Filter posts

With an Air of Optimism, #BIOCEO19 Concludes

Despite considerable pressure directed squarely at biotech innovators from politicians of every stripe, biotech executives …

#BIOCEO19: Navigating Payers’ Expectations for Value-Based Agreements

Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced …

Market Outlook—Leveraging Market Corrections for M&A or IPOs

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year …

#BIOCEO19 Kicks Off in NYC

Pharmaceutical innovation is not slowing down. Last year the FDA approved a total of 59 …

Meet Kallyope’s Nancy Thornberry, Fireside Chat Speaker at #BIOCEO19

Biotech startups come in all shapes, sizes and approaches but have one thing in common: …

Meet Synlogic’s Aoife Brennan, Fireside Chat Speaker at #BIOCEO19

Dr. Aoife Brennan has always faced challenges head-on. A trained endocrinologist, she could have remained …

Using Decision Science for Negotiations: Getting to Win-Win

New medicines often progress from idea to regulatory approval through collaborative licensing agreements or acquisition.  …

Investors lining up for BIO CEO & Investor Conference

The past year has been a transformative one for the life sciences. Despite being faced …

Meet Opiant’s Roger Crystal, Fireside Chat Speaker at #BIOCEO19

When pop star Demi Lovato experienced an apparent opioid-related overdose last summer, reports stated that …

It Starts with One—Partnering Meeting Leads to Unique Public-Private Partnership

Roy Zwahlen took a long shot when he requested a meeting with an investment firm …